Benefits
Supports Energy Metabolism
Niacin is the precursor of the coenzymes NAD and NADP, which more than 400 enzymes use to turn carbohydrates, fats and proteins into usable energy (ATP). This is a nutrient role: getting enough niacin supports normal energy metabolism, but whether extra niacin raises energy in people who already meet their needs is uncertain, and no fatigue trial is cited here.
Blood lipid changes at prescription doses
Gram doses of nicotinic acid lower LDL cholesterol and triglycerides and raise HDL. In two large trials (AIM-HIGH and HPS2-THRIVE), adding niacin to a statin did not reduce heart attacks, strokes or cardiovascular deaths, and HPS2-THRIVE found more serious adverse events. These are prescription-level doses, used only under medical supervision, and current guidelines do not recommend them as an add-on to statins.
Required for normal skin
Niacin is needed to maintain normal skin: severe deficiency (pellagra) causes a rash on sun-exposed skin that clears when niacin is restored. In people who already get enough niacin from food, no benefit beyond correcting a shortfall has been tested in controlled trials, so extra niacin for skin is uncertain.
Needed for Normal Nervous System Function
Severe niacin deficiency (pellagra) causes neurological symptoms such as depression, apathy, headache, fatigue and memory loss, which shows niacin is needed for normal nervous system function. Claims that extra niacin protects against age-related brain diseases such as Alzheimer's rest on animal studies and have not been shown in people.
Supports Enzymes That Maintain DNA
Niacin is turned into NAD, which is required by enzymes involved in keeping the genome intact, controlling gene expression and cell communication. Getting enough niacin supports these normal roles; no trial cited here shows that extra niacin improves DNA repair or cell health in people who already get enough.
Raises Blood Sugar at High Doses
High-dose niacin impairs glucose tolerance and raises blood sugar. In the HPS2-THRIVE trial it increased new diabetes diagnoses by 1.3 percentage points and serious disturbances in diabetes control by 3.7 percentage points. It is not a blood-sugar-lowering supplement, and anyone taking high doses needs blood-glucose monitoring.
Mechanism of action
Coenzyme Formation
Niacin is converted into nicotinamide adenine dinucleotide (NAD) and NADP, coenzymes critical for over 400 enzymatic reactions. These coenzymes act as electron carriers in redox reactions.
Energy Metabolism
NAD is vital for glycolysis, the citric acid cycle, and oxidative phosphorylation, facilitating the breakdown of carbohydrates, fats, and proteins to produce ATP, the cell’s energy currency. NADP supports biosynthetic pathways, such as fatty acid and cholesterol synthesis.
Lipid Regulation (Nicotinic Acid Form)
Nicotinic acid binds receptors (HCAR2, also called GPR109A) that nicotinamide does not bind, which is why only nicotinic acid changes blood lipids. At gram doses taken for months it raises HDL cholesterol by 10% to 30% and lowers LDL by 10% to 25% and triglycerides by 20% to 50%. Activation of the same receptor on skin immune cells releases prostaglandins, which causes the flush.
DNA Maintenance and Cell Signaling
Besides its role in energy reactions, NAD is required by enzymes involved in maintaining genome integrity, controlling gene expression and cell communication.
Neurological and Skin Health
Severe niacin deficiency causes a pigmented rash on sun-exposed skin and neurological symptoms such as depression, apathy and memory loss, which shows niacin is needed for normal skin and nervous system function.
Clinical trials
Randomized placebo-controlled trial run from 1966 to 1975 that tested five lipid-influencing drugs, including niacin, in 8,341 men aged 30 to 64 with a previous heart attack; this report followed mortality for a mean of 15 years. (Canner et al. 1986, J Am Coll Cardiol)
8,341 men with prior MI.
Niacin modestly reduced nonfatal repeat heart attacks during the trial but did not lower total mortality while it was taken. With a mean of 15 years of follow-up, about 9 years after the trial ended, all-cause mortality was 11% lower than with placebo (52.0% versus 58.2%). The trial predates statins; later trials adding niacin to statins found no reduction in cardiovascular events.
Randomized placebo-controlled trial in 3,414 statin-treated patients with cardiovascular disease and low HDL: extended-release niacin 1,500 to 2,000 mg a day or placebo, mean follow-up 3 years. (Boden et al. 2011, N Engl J Med)
3,414 statin-treated CVD patients.
Niacin raised HDL (median 35 to 42 mg/dL) and lowered triglycerides and LDL at 2 years, but the primary composite of cardiovascular events occurred in 16.4% with niacin and 16.2% with placebo (hazard ratio 1.02). The trial was stopped early for lack of efficacy.
Randomized placebo-controlled trial in 25,673 adults with vascular disease on statin-based therapy: 2 g a day extended-release niacin with laropiprant (a drug to reduce flushing) or placebo, median follow-up 3.9 years. (Landray et al. 2014, N Engl J Med)
25,673 high-risk vascular disease patients.
Major vascular events occurred in 13.2% with niacin-laropiprant and 13.7% with placebo (rate ratio 0.96, not significant). Niacin-laropiprant increased serious disturbances in diabetes control (3.7 percentage points), new diabetes diagnoses (1.3 points), and serious gastrointestinal, musculoskeletal, skin, infection and bleeding events.
Study in 5xFAD mice, a model of Alzheimer's disease, testing the niacin receptor HCAR2 and prescription extended-release niacin (Niaspan). (Moutinho et al. 2022, Sci Transl Med)
5xFAD mice, an animal model; not a human trial.
Niaspan reduced amyloid plaque burden and neuron loss and rescued working-memory deficits in the mice, while mice lacking the receptor fared worse. This is animal evidence only and does not show that niacin protects memory in people.
Population-based cohort of 26,746 US adults from NHANES 2003 to 2018 (median follow-up 9.17 years) relating dietary niacin intake to mortality. (Lin et al. 2024, Sci Rep)
26,746 US adults. Cohort.
The highest quarter of dietary niacin intake had lower all-cause mortality (HR 0.74) and cardiovascular mortality (HR 0.73) than the lowest quarter. This is observational: it cannot show cause and effect, niacin intake tracks with overall diet quality, and it says nothing about high-dose supplements.